|Application ||WB, IHC|
|Calculated MW||38378 Da|
|Homology||Mouse - 13/15 amino acid residues identical.|
|Other Names||B1 bradykinin receptor, B1R, BK-1 receptor, Kinin B1 receptor, KB1, Bdkrb1, B1bkr, Bkr|
|Related products for control experiments||Control peptide antigen (supplied with the antibody free of charge).|
|Target/Specificity||Peptide (C)KEAS RTR*SG GPKGS K, corresponding to amino acid residues 243-257 of rat BKRB1 with replacement of cysteine 250 (C250) with serine (*S) (Accession P97583). 3rd intracellular loop.Might not recognize the human epitope.|
|Peptide Confirmation||Confirmed by amino acid analysis.|
|Application Details||Immunohistochemistry (IH): - Rat lung sections (see Duehrkop, C. et al. (2013) in Product Citations). - Mouse spinal cord. Also tested in B1R-/- mice (1:200), (see Dutra, R.C. et al. (2013) in Product Citations).|
|Format||Affinity purified antibody, lyophilized powder|
|Reconstitution||50 µl or 0.2 ml deionized water, depending on the sample size.|
|Antibody Concentration After Reconstitution||0.8 mg/ml.|
|Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Storage After Reconstitution||The reconstituted solution can be stored at 4ºC for up to 2 weeks. For longer periods, small aliquots should be stored at -20ºC or below. Avoid multiple freezing and thawing. The further dilutions should be made using a carrier protein such as BSA (1%). Centrifuge all antibody preparations before use (10000 × g 5 min).|
|Control Antigen Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Control Antigen Reconstitution||100 µl water.|
|Control Antigen Storage After Reconstitution||-20ºC.|
|Preadsorption Control||1 µg peptide per 1 µg antibody.|
|Formulation||Lyophilized powder. Reconstituted antibody contains phosphate buffered saline (PBS), pH 7.4, 1% BSA, 0.05% NaN3.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Kinins are small peptides rapidly produced following tissue injury that serve as important modulators of inflammation and pain. In the periphery, the actions of kinins include vasodilatation, increased vascular permeability, stimulation of immune cells, and induction of pain. Kinins in the central nervous system (CNS) appear to initiate a similar cascade of events leading to neural tissue damage as well as long lasting disturbances affecting blood-brain barrier function.1 Kinins such as Bradykinin (BK), Lys-BK, desArg9-BK, and Lys-desArg9-BK exert their action via two distinct receptors: the B1 Bradykinin receptor (BKRB1) and the B2 Bradykinin receptor (BKRB2). The desArg9-BK and Lys-desArg9-BK peptides activate BKRB1 while BK and Lys-BK operate by activating BKRB2.2 Both BKRB1 and BKRB2 are members of the seven-transmembrane domain, G protein-coupled receptor (GPCR) superfamily and share a common structure of seven putative transmembrane domains, an extracellular amino terminus, and a cytoplasmic carboxyl terminus. Expression of BKRB1is inducible upon various types of tissue injury and by inflammatory mediators such as bacterial lipopolysaccharide (LPS) and cytokines. BKRB1 was long considered not to be expressed in healthy tissues. However, recent work has demonstrated a low level of expression of BKRB1 in the CNS of rodent and primates. In contrast, BKRB2 is constitutively expressed on various cell types.3 BKRB1 represents a potential therapeutic target for treatment of inflammatory disorders and cardiovascular diseases.
1. Walker, K. et al. (1995) Neurochem. Int. 26, 1.
2. Böckmann, S. and Paegelow, I. (2000) J. Leukoc. Biol. 68, 587.
3. Hess, J.F. et al. (2004) J. Pharmacol. Exp. Ther. 310, 488.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.